ArticleClinical journal of gastroenterology2025
Enhanced activity of autoimmune gastritis following Helicobacter pylori eradication therapy.
Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of Gastric Neoplasms in Patients with Autoimmune Gastritis: A Systematic Review and Meta-Analysis.Gut and liver · 2026Pooled it
- Helicobacter pylori Gastritis as an Initial Presentation of Evolving Autoimmune Gastritis: A Report of Two Cases.Internal medicine (Tokyo, Japan) · 2026Article
- The prevalence and associated factors of autoimmune gastritis: single-center, hospital-based prospective study in China.BMC gastroenterology · 2025Article
- Autoimmune Gastritis: Unveiling the Mystery.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Atrophic gastritis of distinct etiologies: malignant potential inAnnals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between autoimmune gastritis (AIG) and Helicobacter pylori (H. pylori) gastritis remains unclear, particularly whether there is any interaction. Herein, we report a case of early-stage AIG diagnosed in an elderly patient with highly active H. pylori gastritis, who subsequently underwent eradication therapy. We were able to follow the changes in these two types of gastritis immediately before and after eradication therapy, through observation over a period of 5 years and 5 months. Despite the previous state of predominant H. pylori gastritis, eradication therapy led to rapid exacerbation of atrophic changes, which was especially evident in endoscopic findings. In addition, the anti-parietal cell antibody titer increased constantly from 1:320 to 1:1280. We concluded that AIG activity was enhanced compared to that before eradication therapy. This course suggests the following two possibilities: early-stage AIG may have progressed steadily regardless of H. pylori gastritis status, or its activity may have been suppressed until the time of eradication therapy.
Indexed as
Identifiers
39806234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.